Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

The UAB Center for Pediatric-Onset Demyelinating Disease (CPODD) is one of the founding Pediatric Multiple Sclerosis (MS) Centers of Excellence in the country designated and funded in 2006 by the ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

Zai Lab (NASDAQ:ZLAB) stock rose 5% in early trading Monday after the company announced that Vyvgart Hytrulo’s regulatory ...

Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report) and keeping the price target at ...

慢性炎性脱髓鞘性多发性神经根神经病（CIDP）是一种罕见的由免疫介导的脱髓鞘性周围神经病1。CIDP患者会经历一系列的行动和感觉问题，包括从坐姿站起来困难、疼痛和疲劳、经常绊倒或摔倒。随着疾病进展，许多患者需依赖轮椅且无法工作，对患者造成严重的疾病负 ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...

KORU Medical Systems (NASDAQ:KRMD – Get Free Report) will release its earnings data after the market closes on Wednesday, ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is ...